Resources

Publications

12/04/2020
- Oncology
Unstable Mutational Profile and Heterogeneity of Residual Breast Tumor Following Neoadjuvant Therapy From Comprehensive Genomic and Transcriptomic Sequencing
San Antonio Breast Cancer 2020
12/04/2020
- Oncology
Concordance and Use Patterns of Tissue and Cell-Free Based Genomic Testing in Metastatic Breast Cancer
San Antonio Breast Cancer Symposium 2020
12/04/2020
- Oncology
Ongoing Partial Response at 6 Months to Olaparib for Metastatic Melanoma With Somatic PALB2 Mutation After Failure of Immunotherapy: A Case Report
Annals of Oncology
12/04/2020
- Oncology
Next Generation Sequencing (NGS) in Older Adults With Breast Cancer Using Tissue-Based and Circulating Tumor DNA (ctDNA) Assays
San Antonio Breast Cancer 2020
12/04/2020
- Oncology
Novel Genomic Variants and Pathways Associated With Baseline Serum Thymidine Kinase 1 Levels in HR-Positive HER2-Negative MBC Patients Commencing Palbociclib and Letrozole
SABCS Annual Meeting 2020
12/01/2020
- Oncology
Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
11/12/2020
- Cardiology
Prediction of Incident AF With Deep Learning Can Identify Patients at High Risk for AF-related Stroke
American Heart Association Scientific Sessions 2020
11/01/2020
- Oncology
Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-small Cell Lung Cancer (COSINR Study)
ASTRO Annual Meeting 2020
10/19/2020
- Oncology
Targeted Next-Generation Sequencing (NGS) of 105 Cancer-Related Genes in Circulating Tumor DNA (ctDNA) From Patients With Advanced Cancers Treated With Immune Checkpoint Inhibitors (iCPI)
AACR Tumor Immunology and Immunotherapy 2020
10/02/2020
- Oncology
Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1–Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti–PD-1 Monoclonal Antibody Therapy
JCO Precision Oncology

60 61 62